FDA in the US has approved a drug that can delay the onset of Type 1 Diabetes. This new drug named teplizumab is not yet available on the market, but can delay the onset of Diabetes by an average of 2 years and in some cases, much longer up to 11 years. The drug is a monoclonal antibody that targets certain lymphocytes that are thought to be the ones that destroy insulin producing cells in the pancreas.
A small study in the New England Journal of Medicine first reported on the effects of
anti-CD3 monoclonal antibodies on new onset of Type 1 Diabetes Mellitus.
Comment: This approach shows great promise in the future prevention of Type 1 Diabetes in susceptible individuals.